Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration

Sara J Haug, Doan Luong Hien, Gunay Uludag, Than Trong Tuong Ngoc, Sherin Lajevardi, M Sohail Halim, Yasir J Sepah, Diana V Do, Arshad M Khanani, Sara J Haug, Doan Luong Hien, Gunay Uludag, Than Trong Tuong Ngoc, Sherin Lajevardi, M Sohail Halim, Yasir J Sepah, Diana V Do, Arshad M Khanani

Abstract

Purpose: To describe retinal arterial occlusion and vasculitis following intravitreal brolucizumab administration in a patient with neovascular age-related macular degeneration (nAMD).

Observation: An 88-year-old Caucasian woman with neovascular age-related macular degeneration (nAMD) complained of painless loss of vision with light sensitivity in both eyes (OU) four weeks after bilateral intravitreal brolucizumab. Upon examination, her visual acuity decreased to 20/40 in the right eye (OD) and 20/50 in the left eye (OS). Examination revealed 0.5+ and 1+ anterior chamber cells in OD and OS, respectively. The patient was treated with 1% prednisolone acetate eyedrops in both eyes, and after several weeks, the anterior chamber cells resolved. However, the patient still reported a decline in visual acuity (VA). Fluorescein angiography (FA) revealed retinal arterial occlusion, vasculitis, and optic nerve inflammation in the left eye. Retinal intra-arterial grayish materials were also detected. Laboratory evaluations were performed for common infectious and inflammatory causes and were normal or negative. A delayed inflammatory reaction to brolucizumab was suspected as the cause of the ocular inflammation and retinal vasculitis. An intravitreal dexamethasone implant was inserted into the left eye to treat the inflammation. One week after the dexamethasone implant, VA improved to 20/40 in OU; FA showed improvement, but residual peri-vascular leakage remained.

Conclusion: Medication-associated uveitis is a rare adverse effect that can lead to vision loss. The index report illustrates a case of intraocular inflammation, retinal arterial vaso-occlusion and vasculitis associated with intravitreal brolucizumab. The delay in developing uveitis suggests that the inflammation is due to a delayed hypersensitivity reaction which can occur several days or weeks after administration of the inciting agent. Recently, several cases of uveitis and vasculitis associated with brolucizumab have been presented and those cases have similar features compared to the index case (1). Therapy with steroids (either intraocular or systemic), after infectious etiologies have been excluded, may be beneficial in halting inflammation and preventing further vision loss.

Keywords: Age-related macular degeneration; Brolucizumab; Intraocular inflammation; Occlusive vasculitis; Retinal vasculitis.

Conflict of interest statement

The authors declare that there are no conflicts of interest related to this article.

© 2020 The Authors.

Figures

Fig. 1
Fig. 1
Optical coherence tomography (Spectralis; Heidelberg Engineering, Heidelberg, Germany) of the right (OD) and left (OS) eyes. Before intravitreal brolucizumab injection in both eyes (row A), after 4 weeks (row B), after 6 weeks (row C), after 8 weeks and before intravitreal dexamethasone implant in OS (row D), two weeks post-intravitreal dexamethasone implant (row E).
Fig. 2
Fig. 2
Fundus photos and fluorescein angiography of the right eye (RE) 8 weeks after intravitreal brolucizumab (top row), one weeks later (middle row) and two weeks later (bottom row) showing area of pigmentary changes (A and C), supratemporal retinal vessel sheathing (black arrow-A). Staining of a segment of the superior arcade retinal arterial (white arrow) is noted in the late phase, (C and F) which resolved spontaneously after 2 weeks (I).
Fig. 3
Fig. 3
Fundus photos and fluorescein angiography of the left eye 8 weeks after intravitreal brolucizumab and before intravitreal dexamethasone implant (top row), showing discrete intraarterial grayish materials (gold arrows-A), retinal vessel sheathing and superior optic nerve edema (blue arrow-A) and vasculitis with vascular and superior optic nerve leakage (white arrow-C). One week after dexamethasone implant (middle row), sheathing of temporal retinal arcade and superior optic nerve edema (blue arrow-D) were still present. Much improved but persistent peri-vascular and optic disc leakage, and temporal retinal vaso-obliteration in the late phase (white arrow-F) with visible intraarterial grayish materials (black arrow-F). At two weeks (bottom row) the inferior temporal retinal artery showed delayed filling (red arrow-H) compared to the superior temporal retinal artery (green arrow-H) and intraarterial blockages in late phase (black arrow-I). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

References

    1. Dugel P.U. Presented at the 2020 Meeting of the Macula Society, March 19 to 22, San Diego, California. 2017. Expanded week 96 safety outcomes: analysis of pooled data from HAWK & HARRIER studies.
    1. Dugel P.U., Koh A., Ogura Y. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84.
    1. Nguyen Q.D., Das A., Do D.V. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration [published online ahead of print, 2020 Jan 17] Ophthalmology. 2020 S0161-6420(20)30041-5.
    1. Nicolcescu A., Mocanu C., Dinu L., Olaru A., Ionete M., Stefanescu D.A. Unilateral Eales' disease a case report. Rom J Ophthalmol. 2017;61(2):144–149.
    1. Veramme J., de Zaeytijd J., Lambert J., Lapeere H. Contact dermatitis in patients undergoing serial intravitreal injections. Contact Dermatitis. 2016;74(1):18–21.
    1. Kleris R.S., Keswani A., Lugar P. The eyes have it: eyelid swelling and rash in a 79-year-old woman with macular degeneration. Allergy & rhinology (Providence, RI) 2018;9 2152656718763385.
    1. Nagai N., Ibuki M., Shinoda H., Kameyama K., Tsubota K., Ozawa Y. Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: a case report. Medicine (Baltim) 2017;96(21) e6965-e.
    1. Meredith G.G., Schkade P.A., Joondeph B.C. Allergic reaction UPON intravitreal administration OF anti-vascular endothelial growth factor Agents. Retin Cases Brief Rep. 2019;13(3):287–289.
    1. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.
    1. Dugel P.U., Jaffe G.J., Sallstig P. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–1304.
    1. Holz F.G., Dugel P.U., Weissgerber G. Single-chain antibody fragment vegf inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;123(5):1080–1089.
    1. Semeraro F., Morescalchi F., Duse S., Parmeggiani F., Gambicorti E., Costagliola C. Aflibercept in wet AMD: specific role and optimal use. Drug Des Dev Ther. 2013;7:711–722.
    1. Auf der Maur A., Escher D., Barberis A. Antigen-independent selection of stable intracellular single-chain antibodies. FEBS Lett. 2001;508(3):407–412.
    1. Thiel M.A., Coster D.J., Standfield S.D. Penetration of engineered antibody fragments into the eye. Clin Exp Immunol. 2002;128(1):67–74.
    1. de Andrade F.A.F.S., Benchimol E.I., Fiorot S.H., Provenzano J., Martins V.J., Levy R.A. The autoimmune diseases of the eyes. Autoimmun Rev. 2016;15:258–271.
    1. Smith R.S., Rudt L.A. Ocular vascular and epithelial barriers to microperoxidase. Invest Ophthalmol Vis Sci. 1975;14(7):556–560.
    1. Taylor A.W., Streilein J.W., Cousins S.W. Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Neuroimmunomodulation. 1994;1(3):188–194.
    1. Taylor A.W. Modulation of regulatory T cell immunity by the neuropeptide alpha-melanocyte stimulating hormone. Cell Mol Biol. 2003;49(2):143–149.
    1. Nishida T., Miyata S., Itoh Y. Anti-inflammatory effects of alpha-melanocyte-stimulating hormone against rat endotoxin-induced uveitis and the time course of inflammatory agents in aqueous humor. Int Immunopharm. 2004;4(8):1059–1066.
    1. Taylor A.W. Alpha-melanocyte stimulating hormone (alpha-MSH) is a post-caspase suppressor of apoptosis in RAW 264.7 macrophages. PloS One. 2013;8(8)
    1. Van Dooremall J.C. Die entwicklung der in fremden grund versetzten lebenden gewebe. Albrecht Von Graefes Arch Ophthalmol. 1873;19:358–373.
    1. Medawar P.B. A second study of the behaviour and fate of skin homografts in rabbits: a Report to the War Wounds Committee of the Medical Research Council. J Anat. 1945;79(Pt 4):157–1576.4.
    1. Medawar P.B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29(1):58–69.
    1. Kwon J.-W., Jee D. Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment. PloS One. 2018;13(9) e0203408-e.
    1. Shin E.S., Sorenson C.M., Sheibani N. Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res. 2014;9(3):362–373.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다